Staff Endocrinologist, Ochsner Health Center-Slidell

Dr. Gabriel Uwaifo is a board-certified internist and endocrinologist who completed undergraduate medical training at the University of Ibadan in Nigeria. He subsequently completed general medicine residency training at the University College Hospital in Ibadan, Nigeria before completing an internal medicine residency at the University of Connecticut Health Center in Farmington, CT.

After serving as a chief resident at the University of Connecticut Health Center, he completed a clinical and research endocrinology and diabetes fellowship at the National Institutes of Health in Bethesda, MD.

He currently sees patients in the domains of Endocrinology, Diabetes, Metabolism and Medical weight management at the Ochsner Health Center-Slidell, is an Associate Clinical Professor with the University of Queensland Ochsner clinical school and also does clinical research work including clinical trials at the Ochsner Medical Center main campus and Ochsner Baptist Clinical Trials Unit in New Orleans.

He has served as principal investigator or substantive co-investigator in over 100 clinical research studies (including industry and NIH funded studies) over the last 15 years, has presented numerous abstracts at various national and regional clinical scientific meetings and has over 100 scientific publications including over 70 peer reviewed manuscripts, book chapters and online scientific monographs.

Selected Publications

Long-term Effects of Metformin on Diabetes Prevention: Identification of Subgroups That Benefited Most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study.
Diabetes Prevention Program Research Group. (member of research group)
Diabetes Care. 2019 Apr;42(4):601-608. doi: 10.2337/dc18-1970.

A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk.
Redondo MJ, Geyer S, Steck AK, Sharp S, Wentworth JM, Weedon MN, Antinozzi P, Sosenko J, Atkinson M, Pugliese A, Oram RA; Type 1 Diabetes TrialNet Study Group. (member of research group)
Diabetes Care. 2018 Sep;41(9):1887-1894. doi: 10.2337/dc18-0087. Epub 2018 Jul 12.

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
Hernandez AF, Green JB, Janmohamed S, D'Agostino RB Sr, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM, McMurray JJV, Del Prato S; Harmony Outcomes committees and investigators. (member of research group)
Lancet. 2018 Oct 27;392(10157):1519-1529. doi: 10.1016/S0140-6736(18)32261-X. Epub 2018 Oct 2.

Differences in short-term food preferences following vertical sleeve gastrectomy and Roux-en-Y gastric bypass surgery.
Primeaux SD, Tzeng TH, Allerton TD, Chiang MC, Cosentino G, Dubin RL, Varughese A, Moore R, Geiselman PJ, Greenway FL, Uwaifo GI.
Obes Res Clin Pract. 2015 Nov-Dec;9(6):628-32. doi: 10.1016/j.orcp.2015.09.003. Epub 2015 Sep 19.

Hypercortisolism in obesity-associated hypertension.
Varughese AG, Nimkevych O, Uwaifo GI.
Curr Hypertens Rep. 2014 Jul;16(7):443. doi: 10.1007/s11906-014-0443-y. Review.

Phentermine and topiramate for the management of obesity: a review.
Cosentino G, Conrad AO, Uwaifo GI.
Drug Des Devel Ther. 2011 Apr 5;7:267-78. doi: 10.2147/DDDT.S31443. Print 2013. Review.

Prevalence and cardiometabolic associations of the glucocorticoid receptor gene polymorphisms N363S and BclI in obese and non-obese black and white Mississippians.
Melcescu E, Griswold M, Xiang L, Belk S, Montgomery D, Bray M, Del Ben KS, Uwaifo GI, Marshall GD, Koch CA.
Hormones (Athens). 2012 Apr-Jun;11(2):166-77.